Katie Dahlstrom
Technik-/Wissenschafts-/F&E-Leiter bei THESEUS PHARMACEUTICALS, INC.
Profil
Katie Dahlstrom is currently the Vice President-Clinical Development Operations at Theseus Pharmaceuticals, Inc. Previously, she worked as the Senior Director-Clinical Operations at Agios Pharmaceuticals, Inc. She completed her undergraduate degree at Stonehill College, Inc. and her graduate degree at Boston University School of Medicine.
Aktive Positionen von Katie Dahlstrom
Unternehmen | Position | Beginn |
---|---|---|
THESEUS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Katie Dahlstrom
Unternehmen | Position | Ende |
---|---|---|
AGIOS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Katie Dahlstrom
Stonehill College, Inc. | Undergraduate Degree |
Boston University School of Medicine | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AGIOS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |